Product Description
Overall, the global cardiac leads market was valued at $1.4 billion in 2021. This is expected to increase over the forecast period at a CAGR of 2.3% to reach $1.7 billion.
Throughout this medical market research, we analyzed global cardiac leads companies across more than 70 countries and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts.
The full report suite on the global market for cardiac leads includes cardiac leads, pacing leads, defibrillation leads and left ventricle (LV) leads.
MARKET REPORT DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- COVID-19 Impact Analysis
- Market Drivers & Limiters
- Market Forecasts Until 2028, and Historical Data to 2018
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
GLOBAL CARDIAC LEADS MARKET TRENDS
Cardiovascular disease is much more prevalent among patients over 55 years of age; therefore, as the population ages, the incidence of cardiovascular disease will increase. In addition, rising rates of obesity will also contribute to the incidence of heart disease. The use of cardiac leads is proportional to the use of pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices. As the population ages, the prevalence of these devices will continue to grow, increasing the number of cardiac leads being implanted.
GLOBAL CARDIAC LEADS MARKET SHARE INSIGHTS
The global cardiac leads market was controlled by three key competitors – Medtronic, Abbott, and Boston Scientific.
In 2021, Medtronic was the leader of the cardiac lead market. Medtronic sells a range of devices, including Sprint Quattro®, as well as the CapSure™ family of pacing leads and the Attain™ family of LV leads.
GLOBAL CARDIAC LEADS MARKET SEGMENTATION SUMMARY
- Cardiac Leads
- Pacing Leads
- Defibrillation Leads
- Left ventricle (LV) leads
RESEARCH SCOPE SUMMARY
Report Attribute | Details |
---|---|
Regions | North America (Canada, United States) Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.) Central & Eastern Europe (Baltic States, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam) Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
Base Year | 2021 |
Forecast | 2022-2028 |
Historical Data | 2018-2021 |
Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
Qualitative Coverage | COVID19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
WHY CHOOSE IDATA?
- Experts Only – iData has been around for over 17 years and is the trusted source of intelligence, and data-driven insights for key industry players. We are made up of specialists with a sole focus on medical devices, dental devices and pharmaceuticals. Our research and consulting field of endeavour never strays from the medical device industry and, because of this, we are the number one choice for leading companies in this field.
- Global Coverage – iData’s unique methodology, and its expansion to over 70 countries world-wide, has made it one of the most viable sources of intelligence for global companies along with those who plan to expand their portfolio beyond the confines of their own country. Providing procedural data at the country level is another testimony to the trusted global coverage we provide.
- Attention to Detail – It’s our attention to small details, scheduling of timelines, and keen project management that makes us stand out from the rest. We are creative, and our reports include metrics such as procedure numbers, ASPs, and SKU-level insights that are not found elsewhere.
- Pricing – When comparing like-with-like, iData’s prices are not only extremely competitive but also the most cost-effective. We strive for success and want the same for our clients. With the level of detail incorporated into each report alongside the extensive segmentation provided, no other report compares at our price point.